Director Shareholding
Cambridge Antibody Tech Group PLC
10 February 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
John Stocker
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Greenwood Nominees Limited
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
207
8) Percentage of issued class
0.0004%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£7.525
13) Date of transaction
10 February 2005
14) Date company informed
10 February 2005
15) Total holding following this notification
82,186
16) Total percentage holding of issued class following this notification
0.159
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee is
well established. In November 2004 the Board resolved that such issue of shares
would occur on a quarterly rather than an annual basis. The share price used is
the average closing price of one CAT share for the three trading days preceding
10 February 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..10 February 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
ke Stavling
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Greenwood Nominees Limited
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
207
8) Percentage of issued class
0.0004%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£7.525
13) Date of transaction
10 February 2005
14) Date company informed
10 February 2005
15) Total holding following this notification
2,342
16) Total percentage holding of issued class following this notification
0.005%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee is
well established. In November 2004 the Board resolved that such issue of shares
would occur on a quarterly rather than an annual basis. The share price used is
the average closing price of one CAT share for the three trading days preceding
10 February 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..10 February 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Sir Aaron Klug
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Greenwood Nominees Limited
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
207
8) Percentage of issued class
0.0004%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£7.525
13) Date of transaction
10 February 2005
14) Date company informed
10 February 2005
15) Total holding following this notification
31,514
16) Total percentage holding of issued class following this notification
0.061%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee is
well established. In November 2004 the Board resolved that such issue of shares
would occur on a quarterly rather than an annual basis. The share price used is
the average closing price of one CAT share for the three trading days preceding
10 February 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..10 February 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Peter Ringrose
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Greenwood Nominees Limited
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
207
8) Percentage of issued class
0.0004%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£7.525
13) Date of transaction
10 February 2005
14) Date company informed
10 February 2005
15) Total holding following this notification
3,162
16) Total percentage holding of issued class following this notification
0.006%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee is
well established. In November 2004 the Board resolved that such issue of shares
would occur on a quarterly rather than an annual basis. The share price used is
the average closing price of one CAT share for the three trading days preceding
10 February 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..10 February 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Professor Christopher Marshall
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Greenwood Nominees Limited
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
207
8) Percentage of issued class
0.0004%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£7.525
13) Date of transaction
10 February 2005
14) Date company informed
10 February 2005
15) Total holding following this notification
227
16) Total percentage holding of issued class following this notification
0.0004%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee is
well established. In November 2004 the Board resolved that such issue of shares
would occur on a quarterly rather than an annual basis. The share price used is
the average closing price of one CAT share for the three trading days preceding
10 February 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..10 February 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Dr Paul Nicholson
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Dr Paul Nicholson
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
498
8) Percentage of issued class
0.0010%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£7.525
13) Date of transaction
10 February 2005
14) Date company informed
10 February 2005
15) Total holding following this notification
9,610
16) Total percentage holding of issued class following this notification
0.019%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee is
well established. In November 2004 the Board resolved that such issue of shares
would occur on a quarterly rather than an annual basis. The share price used is
the average closing price of one CAT share for the three trading days preceding
10 February 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..10 February 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Professor Uwe Bicker
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
Professor Uwe Bicker
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)
7) Number of shares/amount of
stock acquired
207
8) Percentage of issued class
0.0004%
9) Number of shares/amount
of stock disposed
Nil
10) Percentage of issued class
Nil
11) Class of security
Ordinary 10 pence shares
12) Price per share
£7.525
13) Date of transaction
10 February 2005
14) Date company informed
10 February 2005
15) Total holding following this notification
6,045
16) Total percentage holding of issued class following this notification
0.012%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
18) Period during which or date on which exercisable
19) Total amount paid (if any) for grant of the option
20) Description of shares or debentures involved: class, number
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
22) Total number of shares or debentures over which options held
following this notification
23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee is
well established. In November 2004 the Board resolved that such issue of shares
would occur on a quarterly rather than an annual basis. The share price used is
the average closing price of one CAT share for the three trading days preceding
10 February 2005.
24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Date of Notification..10 February 2005
This information is provided by RNS
The company news service from the London Stock Exchange
Latest directors dealings
- 1 day ago Mattioli Woods
- 1 day ago Morgan Advanced Materials
- 1 day ago Capita
- 1 day ago Judges Scientific
- 1 day ago Me Group International